Archives of Psychiatric Nursing
Volume 24, Issue 1 , Pages 46-53 , February 2010

Nursing Care of Clients Treated with Atypical Antipsychotics Who Have a Risk of Developing Metabolic Instability and/or Type 2 Diabetes

  • Karen-leigh Edward

      Affiliations

    • Corresponding Author InformationCorresponding Author: Karen-leigh Edward, RN, PhD, Centre for Nursing Research, Australian Catholic University, P.O. Box 2900, Fitzroy, Melbourne, Victoria 3065, Australia.
    • ,
  • Bodil Rasmussen
    • ,
  • Ian Munro

References 

  1. ADA . American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(1):s262(266)
  2. AIHW . National indicators for monitoring diabetes: Report of the Diabetes Indicators Review Subcommittee of the National Diabetes Data Working Group (No. CVD 38). Canberra: Australian Institute of Health and Welfare; 2007;
  3. AIHW . Diabetes: Australian facts (No. CVD 40). Canberra: Australian Institute of Health and Welfare; 2008;
  4. Barnes TRE, Paton C, Cavanagh M-R, Hancock E, Taylor DM. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophrenia Bulletin. 2007;33(6):1397–1403
  5. Bushe CJ, Leonard BE. Blood glucose and schizophrenia: A systematic review of prospective randomized clinical trials. The Journal of Clinical Psychiatry. 2007;68(11):1682–1690
  6. Clarke P, Kelman C, Colagiuri S. Factors influencing the cost of hospital care of people with diabetes in Australia. Journal of Diabetes and Its Complications. 2006;20:349–355
  7. Coodin S. Body mass index in persons with schizophrenia. Canadian J Psychiatry. 2001;46(6):549–555
  8. DAWN International Expert Advisory Board . Putting people at the centre of care. Diabetes Voice. 2004;49;[Special issue]
  9. Dunning PL. Care of people with diabetes: A manual of nursing practice. 2nd ed.. Melbourne: Blackwell Publishing; 2003;
  10. Dunstan D, Zimmet P, Welborn T, Sicree R, Armstrong T, Atkins R, et al. Diabesity & associated disorders in Australia—2000: The accelerating epidemic. Melbourne: AusDiab Steering Commitee: International Diabetes Institute; 2001;
  11. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry. 2004;61(11):1107–1115
  12. Haupt DW, Kane JM. Metabolic risks and effects of atypical antipsychotic treatment. The Journal of Clinical Psychiatry. 2007;68(10):e24
  13. Henderson DC, Borba CP, Daley TB, Boxill R, Nguyen DD, Culhane MA, et al. Dietary intake profile of patients with schizophrenia. Annals of Clinical Psychiatry. 2006;18(2):99–105
  14. Henderson DC, Cagliero E, Copeland PM, Louie PM, Borba CP, Fan X, et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. The Journal of Clinical Psychiatry. 2007;68(4):533–541
  15. Jarboe KS. Considering the impact on overall patient health when choosing antipsychotic therapy. Journal of the American Psychiatric Nurses Association. 2007;13(5):S23–S28
  16. Julien RM. A primer of drug action: A comprehensive guide to the actions, uses, and side effects of psychoactive drugs. 11th ed.. New York: Worth Publishers Inc; 2008;
  17. Kilbourne AM, Rofey DL, McCarthy JF, Post EP, Welsh D, Blow FC. Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disorders. 2007;9(5):443–452
  18. Knight KM, Dornan T, Bundy C. The diabetes educator: Trying hard, but must concentrate more on behaviour. Diabetic Medicine. 2006;23:485–501
  19. Montez JK, Karner TX. Understanding the diabetic body-self. Qualitative Health Research. 2005;15(8):1086–1104
  20. Murashita M, Kusumi I, Hosoda H, Kangawa K, Koyama T. Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats. Psychoneuroendocrinology. 2007;32(7):777–784
  21. Murphy H, Murphy EK. Comparing quality of life using the World Health Organization Quality of Life measure (WHOQOL-100) in a clinical and non-clinical sample: Exploring the role of self-esteem, self-efficacy and social functioning. Journal of Mental Health. 2006;15(3):289–300
  22. NASMHPD . Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. National Association of State Mental Health Program Directors. Accessed 20th April 2009 from http://www.nasmhpd.org/general_files/publications/med_directors_pubs/NASMHPD%20Principles%20of%20Antipsychotics%20final.pdf2008;
  23. Newcomer JW, Sernyak MJ. Identifying metabolic risks with antipsychotics and monitoring and management strategies. The Journal Of Clinical Psychiatry. 2007;68(7):e17
  24. Oladele C, Barnett E. Racial/Ethnic and social class differences in preventive care practices among persons with diabetes. BMC Public Health. 2006;6(1):259
  25. Osterberg L, Blaschke T. Adherence to medication. New England Journal of Medicine. 2005;353(5):487–496
  26. Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. The Journal of Clinical Psychiatry. 2007;68(11):1733–1740
  27. Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, et al. Assessing psychosocial distress in diabetes: Development of the Diabetes Distress Scale. Diabetes Care. 2005;28:626–631
  28. Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, et al. Management of antipsychotic-induced weight gain: Prospective naturalistic study of the effectiveness of a supervised exercise programme. Australian and New Zealand Journal of Psychiatry. 2007;41(12):980–989
  29. Rubin RR, Peyrot M. Psychological issues and treatments for people with diabetes. Journal of Clinical Psychology. 2001;57(4):457–478
  30. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: A randomized, double-blind, controlled, prospective study. The Journal of Clinical Psychiatry. 2007;68(11):1793–1798
  31. Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes & Metabolism. 2007;33(3):169–175
  32. Snoek FJ, van Ballegooie EM. Psycho-social care for people with diabetes: What the guidelines say. Diabetes Voice. 2004;49:28–30
  33. Thorne SE, Paterson B, Russell C. The structure of everyday self-care decision making in chronic illness. Qualitative Health Research. 2003;13(10):1337–1352
  34. Trief PM, Morin PC, Izouierdo R, Teresi J, Starren J, Shea S, et al. Marital quality and diabetes outcomes: The IDEATel Project. Families, Systems & Health: The Journal of Collaborative Family HealthCare. 2006;24(3):318–331
  35. Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, et al. Metabolic side effects of antipsychotic medication. International Journal Of Clinical Practice. 2007;61(8):1356–1370
  36. Walker C, Peterson CL, Millen N, Martin C. Chronic illness: New perspectives and new directions. Melbourne: Tertiary Press; 2003;
  37. Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. Clozapine use and risk of diabetes mellitus. Journal of Clinical Psychopharmacology. 2002;22(3):236–243
  38. Wooten J. Metabolic effects of the atypical antipsychotics. Southern Medical Journal. 2007;100(8):771–772
  39. Zimmet P. Diabesity in Australia: An affair of the heart. Heart Lung & Circulation. 2003;12(s2):S95–S98

PII: S0883-9417(09)00064-8

doi: 10.1016/j.apnu.2009.04.009

Archives of Psychiatric Nursing
Volume 24, Issue 1 , Pages 46-53 , February 2010

Article Tools